Breakthrough in Heart Disease Treatment: The Promise of Itaconate

**Researchers at Case Western Reserve University have discovered itaconate's vital role in treating atherosclerosis, a condition characterized by plaque buildup in arteries leading to strokes and heart attacks.** Published in _Cell Reports_, their study found that itaconate, an inflammation-reducing molecule, is integral to diet-induced plaque stabilization. Despite current medications and lifestyle changes, cardiovascular diseases remain the leading cause of death globally. Many struggle with restrictive diets, which are crucial for reducing risks. However, itaconate offers a promising alternative. According to Andrei Maiseyeu, associate professor at the Cardiovascular Research Institute, itaconate significantly enhances a diet's ability to stabilize plaques at a molecular level, a mystery until now. This breakthrough has led to the development of ITA-conjugated lipid nanoparticles (ITA-LNP), which can effectively accumulate in plaque and bone marrow to mimic the benefits of a low-cholesterol/low-fat diet without drastic lifestyle changes. Initial models have shown the treatment's effectiveness, and the team is optimistic about its potential for reducing heart attack and stroke risks while improving patient quality of life. Steps are now underway to translate ITA-LNP into clinical use, potentially offering a convenient pill form.